MaxCyte, Inc. provided revenue guidance for the full year 2022. For the period, the company expected core business revenue (instruments and disposables to cell therapy and drug discovery customers and excluding program-related revenue) to grow at least 25% compared to 2021 core business revenue. The company also continue to expect SPL Program-related revenue to be approximately $4 million in 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
375 GBX | 0.00% | +1.35% | +6.38% |
May. 08 | MaxCyte Shares Rise Sharply After Q1 Results Beat | MT |
May. 08 | MaxCyte shares rise amid double-digit revenue increase | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.38% | 498M | |
+12.15% | 227B | |
+14.90% | 197B | |
+18.22% | 141B | |
+29.15% | 110B | |
+0.53% | 64.15B | |
+16.92% | 53.72B | |
+6.33% | 51.75B | |
+10.93% | 45.2B | |
+5.87% | 37.37B |
- Stock Market
- Equities
- MXCT Stock
- News MaxCyte, Inc.
- MaxCyte, Inc. Provides Revenue Guidance for the Full Year 2022